Free Trial

CARGO Therapeutics (CRGX) Stock Price, News & Analysis

CARGO Therapeutics logo
$4.12 +0.07 (+1.60%)
As of 02:09 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About CARGO Therapeutics Stock (NASDAQ:CRGX)

Key Stats

Today's Range
$4.01
$4.16
50-Day Range
$3.80
$4.64
52-Week Range
$3.00
$25.45
Volume
296,996 shs
Average Volume
535,920 shs
Market Capitalization
$190.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Reduce

Company Overview

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

CARGO Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

CRGX MarketRank™: 

CARGO Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 607th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CARGO Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    CARGO Therapeutics has received no research coverage in the past 90 days.

  • Read more about CARGO Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CARGO Therapeutics are expected to grow in the coming year, from ($3.69) to ($2.27) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CARGO Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CARGO Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CARGO Therapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CRGX.
  • Dividend Yield

    CARGO Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CARGO Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CRGX.
  • News Sentiment

    CARGO Therapeutics has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for CARGO Therapeutics this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    3 people have added CARGO Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CARGO Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.92% of the stock of CARGO Therapeutics is held by insiders.

  • Percentage Held by Institutions

    93.16% of the stock of CARGO Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about CARGO Therapeutics' insider trading history.
Receive CRGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CARGO Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRGX Stock News Headlines

The Secret Map of America, Declassified…
Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “secret America” — an America first envisioned by President Harry Truman in 1946, and then classified by the government for decades.
CARGO Therapeutics Stock (NASDAQ:CRGX) Jumps 20% on Buyout Hopes
See More Headlines

CRGX Stock Analysis - Frequently Asked Questions

CARGO Therapeutics' stock was trading at $14.42 at the beginning of 2025. Since then, CRGX shares have decreased by 71.4% and is now trading at $4.1250.
View the best growth stocks for 2025 here
.

CARGO Therapeutics, Inc. (NASDAQ:CRGX) issued its earnings results on Tuesday, November, 12th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.26.

CARGO Therapeutics (CRGX) raised $281 million in an IPO on Friday, November 10th 2023. The company issued 18,750,000 shares at a price of $15.00 per share.

CARGO Therapeutics' top institutional investors include Cormorant Asset Management LP (7.33%), Nantahala Capital Management LLC (2.39%), Wellington Management Group LLP (2.24%) and Woodline Partners LP (1.84%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Perceptive Advisors Llc, Gina Chapman and Anup Radhakrishnan.
View institutional ownership trends
.

Shares of CRGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CARGO Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
11/12/2024
Today
5/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRGX
Previous Symbol
NASDAQ:CRGX
Fax
N/A
Employees
116
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$33.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+269.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-98,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$9.84 per share
Price / Book
0.41

Miscellaneous

Free Float
45,393,000
Market Cap
$187.21 million
Optionable
N/A
Beta
0.47
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:CRGX) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners